OakChart

BioAge Labs Inc

BIOAHealthcare·Drug Manufacturers - Specialty & Generic·USA·Micro·NASD·Nov 11 • 3:59 PM ET

5.87+0.09 (1.56%)
2026-11-12 03:55 CET
Market cap
269.78 USD m
Revenue, TTM
8.60 USD m
Net income, TTM
-107.80 USD m
Free cash flow, TTM
-103.00 USD m
EPS diluted, TTM
-2.55
P/E
-
Compare

Price

BIOA against its 20, 50 and 200-day averages
2050200miss
5.0010.0015.0020.0025.005.0M10.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BIOAclose 5.8720-day 5.5550-day 6.76200-day 15.255.8752w high52w low

77.4% under the 52-week high of 25.96 on 6 Jul 2026. 52-week low 4.81 on 16 Oct 2026. Last 15 sessions, 28.0% high to low

Volume 0.59× normal · the line is the 50-bar volume average

Profile

BIOA
52-week range, 5% of the way up
4.8125.95

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.

IndexRUT
Employees62
IPOSep 26, 2024
Beta1.19
ATR, 14d0.45
Rel volume0.59
Short float11.85%
Insider own31.58%
Inst own61.62%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap269.78M
Enterprise Value-11.13M
Income-107.80M
Sales8.60M
Book/sh7.54
Cash/sh6.17
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees62
IPOSep 26, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S31.37
P/B0.78
P/C0.95
P/FCF-
EV/EBITDA-
EV/Sales-1.29
Quick Ratio15.51
Current Ratio15.51
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.55
EPS next Y-2.57
EPS next Q-0.74
EPS this Y-16.52%
EPS next Y1.46%
EPS next 5Y-4.97%
EPS past 3/5Y-24.49% -
Sales past 3/5Y- -
EPS Y/Y TTM-20.81%
Sales Y/Y TTM45.33%
EPS Q/Q-29.72%
Sales Q/Q-85.49%
EarningsNov 05 AMC
EPS/Sales Surpr.-15.01% -79.83%

Ownership

Insider Own31.58%
Insider Trans-0.43%
Inst Own61.62%
Inst Trans11.40%
ROA-32.05%
ROE-34.56%
ROIC-30.94%
Gross Margin96.72%
Oper. Margin-1401.81%
Profit Margin-1253.60%
SMA205.75%
SMA50-13.17%
SMA200-61.51%
Trades-

Technical

Shs Outstand45.95M
Shs Float31.44M
Short Float11.85%
Short Ratio5.05
Short Interest3.73M
52W High25.95 -77.38%
52W Low4.81 22.04%
Volatility7.91% 7.89%
ATR (14)0.45
RSI (14)46.87
Beta1.19
Rel Volume0.59
Avg Volume737.94K
Volume436,726

Performance

Perf Week-1.34%
Perf Month5.39%
Perf Quarter-43.72%
Perf Half Y-69.33%
Perf YTD-55.63%
Perf Year-25.03%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.60
Target Price28.56
Prev Close5.78
Price5.87
Change %1.56%

Analyst ratings

latest 10 of 16
DateActionAnalystRating changeTargetImplied
Oct 12, 2026InitiatedUUBSNeutral$8+36.3%
May 27, 2026InitiatedRRoth CapitalBuy$36+513.3%
May 13, 2026InitiatedBBTIG ResearchBuy$40+581.4%
Mar 27, 2026InitiatedNNeedhamBuy$50+751.8%
Feb 25, 2026InitiatedOOppenheimerOutperform$60+922.1%
Feb 18, 2026UpgradeJJefferiesHold → Buy$62+956.2%
Jan 27, 2026InitiatedPPiper SandlerOverweight$73+1,143.6%
Dec 05, 2025UpgradeMMorgan StanleyUnderweight → Equal-Weight$12+104.4%
Oct 22, 2025UpgradeCCitigroupNeutral → Buy$10+70.4%
Feb 28, 2025InitiatedWWilliam BlairMkt Perform

Peers

Mkt cap
TickerCompanyMkt cap
ALTAltimmune Inc375.41M
GPCRStructure Therapeutics Inc ADR1.49B
EYPTEyePoint Inc30.74M
KODKodiak Sciences Inc6.87B
NAMSNewAmsterdam Pharma Company NV2.48B
MLYSMineralys Therapeutics Inc1.43B
OCULOcular Therapeutix Inc1.47B
CRBPCorbus Pharmaceuticals Holdings Inc77.36M
VKTXViking Therapeutics Inc3.63B
NVONovo Nordisk ADR137.48B

Insider trading

latest 14 of 33
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Barton ShanePrincipal Accounting OfficerJun 29 '26Option Exercise6.6139,718262,54242,350Jul 01 04:27 PM
Barton ShanePrincipal Accounting OfficerJun 30 '26Option Exercise6.5320,216132,01720,216Jul 01 04:27 PM
Barton ShanePrincipal Accounting OfficerJun 29 '26Sale25.2142,3501,067,5760Jul 01 04:27 PM
Barton ShanePrincipal Accounting OfficerJun 30 '26Sale25.1920,216509,1760Jul 01 04:27 PM
Barton ShaneOfficerJun 30 '26Proposed Sale25.1920,216509,177Jun 30 04:21 PM
Barton ShaneOfficerJun 29 '26Proposed Sale25.2142,3501,067,578Jun 29 04:35 PM
GOLDSTEIN DOV A MDChief Financial OfficerApr 23 '26Option Exercise4.383,54215,51436,575Apr 24 04:19 PM
RUBIN PAUL DChief Medical OfficerApr 01 '26Option Exercise5.058,82044,5728,820Apr 03 04:07 PM
RUBIN PAUL DChief Medical OfficerApr 01 '26Sale17.818,820157,0840Apr 03 04:07 PM
RUBIN PAUL DOfficerApr 01 '26Proposed Sale17.818,820157,084Apr 01 10:53 AM
RUBIN PAUL DChief Medical OfficerMar 02 '26Option Exercise4.777,43335,4707,433Mar 03 04:46 PM
RUBIN PAUL DChief Medical OfficerMar 02 '26Sale20.307,433150,8900Mar 03 04:46 PM
GOLDSTEIN DOV A MDChief Financial OfficerMar 01 '26Option Exercise4.383,54215,51433,033Mar 03 04:44 PM
RUBIN PAUL DOfficerMar 02 '26Proposed Sale20.037,433148,883Mar 02 10:17 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B

News

latest 14 of 100
  • BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
  • BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire) -6.89%
  • BioArctic collaborator Novartis terminates agreement (PR Newswire)
  • BioArctic's Nomination Committee appointed (PR Newswire)
  • BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
  • BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema (GlobeNewswire)
  • BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
  • Number of shares and votes in BioArctic AB (publ) as of August 31, 2026 (PR Newswire)
  • BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • BIOA, GLUE Stocks Clock Worst Day In Years Whats The NVO Connection? (Stocktwits) -63.62% +19.25%
  • More than 75% of Leqembi-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC 2026 (PR Newswire)
  • BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk (GlobeNewswire)
  • BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
  • Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.730-0.635-0.7130.301.4810
2026Q22026-08-05-0.580-0.607-0.5822.451.5010
2026Q12026-05-08-0.520-0.640-0.5242.771.087
2025Q42026-03-24-0.720-0.738-0.7193.071.407
2025Q32025-11-06-0.560-0.584-0.5632.050.785
2025Q22025-08-06-0.600-0.482-0.6022.410.005
2025Q12025-05-06-0.360-0.529-0.3611.350.005
2024Q42025-03-20-1.077-0.829-0.5890.000.004
2024Q32024-11-07-6.700-0.677-0.6850.000.004
2024Q22024-08-28-0.467--0.3980.00--
2026Q4---0.739--1.0211
2027Q1---0.656--0.297
2027Q2---0.659--0.297
2027Q3---0.613--5.917
2027Q4---0.533--0.276
2028Q1---0.558---2

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-6.630-3.636-1.9840.000.00
2025FY-2.240-2.267-2.1689.007.11
2026FY--2.610--6.67
2027FY--2.572--6.97
2028FY--2.591--2.59
2029FY--2.846--3.69
2030FY--2.758--40.52

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0610011.020.003.11
2026Q4S2026-10-2010001.220.003.11
2026Q4S2026-10-1410101.220.003.11
2026Q4S2026-10-1310201.220.003.11
2026Q4S2026-10-0910211.220.003.11
2026Q4S2026-08-069211.270.003.11
2026Q4S2026-07-319111.240.003.11
2026Q4S2026-07-309011.210.003.11
2026Q4S2026-07-2290053.980.00475
2026Q4S2026-05-2690153.980.00475
2026Q4S2026-05-1280160.610.00475
2026Q4S2026-05-0870168.820.00475
2026Q4S2026-04-2960080.250.00475
2026Q4S2026-04-0261080.250.00475

Estimate history

EPS, annual-1.163-1.867-1.984-2.243-2.5541
Period2022202320242025TTM
EPS, quarterly-0.685-0.589-0.361-0.602-0.563-0.719-0.524-0.582-0.73
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0008.9958.6
Period2022202320242025TTM
Sales, quarterly001.4512.4122.0543.0782.7722.4510.298
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual34.16734.19735.8537.38745.951
Period2022202320242025MRQ
Shares, quarterly34.19735.8535.8535.8535.8537.38744.38745.77745.951
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue8.608.990.000.000.00
Cost of Goods Sold Incl. D&A0.280.210.170.160.13
Gross Profit8.328.78-0.17-0.16-0.13
Selling, General and Administrative Excl. Other128.86101.5678.0348.2439.84
Research and Development99.5173.9759.0433.8930.52
Other Operating Expense0.000.000.000.000.00
Operating Income-120.54-92.78-78.19-48.40-39.97
Interest Expense0.130.702.377.790.24
Unusual Expense0.010.210.1810.09-0.02
Net Income Before Taxes-107.80-80.61-71.11-63.85-39.72
Income Taxes0.000.000.000.000.00
Consolidated Net Income-107.80-80.61-71.11-63.85-39.72
Net Income From Continuing Operations-107.80-80.61-71.11-63.85-39.72
Net Income-107.80-80.61-71.11-63.85-39.72
EPS (Recurring)-2.35-2.24-1.98-1.66-1.16
EPS (Basic, Before Extraordinaries)-2.55-2.24-1.98-1.87-1.16
EPS (Diluted)-2.55-2.24-1.98-1.87-1.16
EBITDA-120.26-92.57-78.03-48.24-39.84
Non-Operating Income (Expense)12.8913.099.632.430.47
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense15.8911.696.983.022.54
Price To Sales Ratio37.8552.85---
Gross Margin96.7297.63---
Operating Margin-1,401.81-1,031.46---
Net Margin-1,253.60-896.11---
Shares Outstanding45.9537.3935.8534.2034.17
Market Capitalization269.78269.78207.56202.90-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.302.452.773.082.052.411.450.00
Cost of Goods Sold Incl. D&A0.080.070.060.070.050.060.040.05
Gross Profit0.222.382.713.012.002.351.41-0.05
Selling, General and Administrative Excl. Other37.6331.7128.0831.4325.1427.1217.8625.32
Research and Development30.2324.3620.4124.5018.5119.8411.1119.23
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-37.41-29.33-25.38-28.42-23.14-24.77-16.45-25.36
Interest Expense0.000.000.040.090.150.200.260.32
Unusual Expense-0.510.200.110.220.040.01-0.06-0.46
Net Income Before Taxes-33.50-26.10-22.25-25.94-20.17-21.56-12.93-21.13
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-33.50-26.10-22.25-25.94-20.17-21.56-12.93-21.13
Net Income From Continuing Operations-33.50-26.10-22.25-25.94-20.17-21.56-12.93-21.13
Net Income-33.50-26.10-22.25-25.94-20.17-21.56-12.93-21.13
EPS (Recurring)-0.74-0.58-0.52-0.71-0.56-0.60-0.36-0.60
EPS (Basic, Before Extraordinaries)-0.73-0.58-0.52-0.72-0.56-0.60-0.36-0.59
EPS (Diluted)-0.73-0.58-0.52-0.72-0.56-0.60-0.36-0.59
EBITDA-37.33-29.26-25.31-28.35-23.09-24.71-16.41-25.32
Non-Operating Income (Expense)3.393.443.272.793.163.423.714.09
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.644.274.262.722.793.232.952.72
Price To Sales Ratio37.85106.1372.0253.1135.6338.3392.90-
Gross Margin73.1597.1497.7397.7697.6197.6097.45-
Operating Margin-12,554.03-1,196.78-915.40-923.42-1,126.58-1,026.99-1,133.43-
Net Margin-11,242.95-1,064.75-802.78-842.85-982.04-893.99-890.97-
Shares Outstanding45.9545.7844.3937.3935.8535.8535.8535.85
Market Capitalization269.781,089.54776.20474.36210.80148.06134.80207.56

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments281.10354.3524.9627.64
Short Term Receivables1.970.000.000.00
Inventories0.000.000.000.00
Other Current Assets3.732.750.350.39
Total Current Assets286.79357.1025.3128.03
Net Property, Plant & Equipment3.750.790.520.37
Total Investments and Advances4.130.100.100.00
Intangible Assets--0.00-
Deferred Tax Assets0.640.06--
Other Assets0.220.240.000.03
Total Assets295.53358.2925.9228.43
Short Term Debt Incl. Current Port. of LT Debt3.236.2026.870.22
Accounts Payable2.672.001.872.26
Other Current Liabilities14.2319.5829.433.38
Total Current Liabilities20.1427.7758.175.86
Long Term Debt2.332.508.202.25
Provision for Risks Charges0.000.000.000.00
Deferred Tax Liabilities0.640.06--
Other Liabilities0.374.830.230.15
Total Liabilities23.4835.1766.608.27
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.00132.72132.72
Common Equity272.05323.13-173.40-112.56
Total Shareholders Equity272.05323.13-40.6720.16
Accumulated Minority Interest0.000.000.000.00
Total Equity272.05323.13-40.6720.16
Total Liabilities & Stockholders Equity295.53358.2925.9228.43
Book Value Per Share7.289.01-5.07-3.29
Tangible Book Value Per Share7.289.01-5.07-3.29
Full-Time Employees6264--
Price to Book Ratio0.780.630.62-
Return on Assets-24.66-37.01-234.96-
Return on Equity-27.09-50.35--
Return on Invested Capital-29.38-21.84--177.21
Quick Ratio14.2412.860.444.78
Current Ratio14.2412.860.444.78

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-107.80-80.61-71.11-63.85-39.72
Depreciation0.280.210.170.160.13
Other Funds (Non Cash)12.9510.598.2419.622.62
Funds from Operations-94.56-69.80-62.70-44.07-36.98
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital-7.95-11.8311.186.710.80
Cash from Operating Activities-102.52-81.63-51.52-37.36-36.18
Capital Expenditures-0.48-0.72-0.37-0.17-0.10
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments-217.67-94.500.00-0.100.00
Purchase of Investments-385.18-154.750.00-0.100.00
Sale Or Maturity of Investments167.5160.250.000.000.00
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities-218.15-95.22-0.37-0.27-0.10
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock161.9417.47387.200.000.04
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock161.9417.47387.200.000.04
Proceedsfrom Stock Options155.9916.75386.560.000.00
Issuance or Reduction of Debt, Net-4.16-6.00-6.0034.942.46
Change in Long Term Debt-4.16-6.00-6.0011.442.46
Issuance of Long Term Debt0.000.000.0012.442.46
Reduction of Long Term Debt-4.16-6.00-6.00-1.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.00
Cash from Financing Activities157.7811.47381.2034.942.50
Exchange Rate Effect-0.02-0.090.080.000.25
Net Change in Cash-162.91-165.46329.39-2.69-33.54
Free Cash Flow-103.00-82.35-51.89-37.53-36.28
Preferred Dividends (Cash Flow)-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments283.64318.75383.19281.10285.78297.30
Short Term Receivables2.873.122.611.971.611.60
Inventories0.000.000.000.000.000.00
Other Current Assets8.558.446.063.733.442.80
Total Current Assets295.05330.31391.86286.79290.83301.70
Net Property, Plant & Equipment3.613.793.803.753.864.01
Total Investments and Advances68.6862.621.784.1310.1816.21
Deferred Tax Assets---0.64--
Other Assets0.300.210.210.220.230.24
Total Assets367.65396.93397.65295.53305.09322.15
Short Term Debt Incl. Current Port. of LT Debt0.720.711.803.234.716.23
Accounts Payable1.895.653.072.675.021.33
Other Current Liabilities16.4112.8510.9614.2314.7715.28
Total Current Liabilities19.0319.2215.8320.1424.4922.84
Long Term Debt2.012.122.232.332.432.52
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.64--
Other Liabilities0.160.680.480.370.712.01
Total Liabilities21.2022.0218.5323.4827.6327.37
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity346.45374.91379.12272.05277.46294.78
Total Shareholders Equity346.45374.91379.12272.05277.46294.78
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity346.45374.91379.12272.05277.46294.78
Total Liabilities & Stockholders Equity367.65396.93397.65295.53305.09322.15
Book Value Per Share7.548.198.547.287.748.22
Tangible Book Value Per Share7.548.198.547.287.748.22
Full-Time Employees---62--
Price to Book Ratio0.782.872.401.710.720.47
Return on Assets-32.05-26.27-24.26-24.66-23.59-32.48
Return on Equity-34.56-28.21-25.98-27.09-25.64-35.88
Return on Invested Capital-9.61-6.92-5.84-9.46-7.21-7.25
Quick Ratio15.5117.1924.7614.2411.8713.21
Current Ratio15.5117.1924.7614.2411.8713.21

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-33.50-26.10-22.25-25.94-20.17-21.56
Depreciation0.080.070.060.070.050.06
Other Funds (Non Cash)3.513.954.141.362.853.32
Funds from Operations-29.92-22.08-18.05-24.52-17.27-18.18
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.042.82-5.99-3.741.23-1.79
Cash from Operating Activities-30.96-19.26-24.05-28.25-16.04-19.97
Capital Expenditures-0.02-0.33-0.03-0.11-0.02-0.16
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments7.56-164.19-46.73-14.3212.86-15.48
Purchase of Investments-60.87-203.78-80.21-40.32-12.89-23.98
Sale Or Maturity of Investments68.4339.5933.4926.0025.758.50
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities7.54-164.51-46.75-14.4312.84-15.64
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.0817.13125.2217.51-0.040.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.0817.13125.2217.51-0.040.00
Proceedsfrom Stock Options0.0315.65123.5116.80-0.040.00
Issuance or Reduction of Debt, Net0.00-1.16-1.50-1.50-1.50-1.50
Change in Long Term Debt0.00-1.16-1.50-1.50-1.50-1.50
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.00-1.16-1.50-1.50-1.50-1.50
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities2.0815.97123.7216.01-1.54-1.50
Exchange Rate Effect0.04-0.01-0.03-0.02-0.01-0.05
Net Change in Cash-21.30-167.8152.89-26.68-4.76-37.16
Free Cash Flow-30.98-19.59-24.07-28.36-16.07-20.13

Revenue breakdown

Pharmaceutical Preparations2025: 9.00M
United States2025: 9.00M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.85%3.7M31.4M961.94K
2026-10-1510.93%3.4M31.4M919.14K
2026-09-3010.59%3.3M30.9M856.02K
2026-09-159.94%3.1M30.9M872.27K
2026-08-318.80%2.7M30.9M845.37K
2026-08-147.17%2.2M30.9M832.70K
2026-07-317.85%2.6M32.7M703.63K
2026-07-157.74%2.5M31.7M522.03K
2026-06-3011.82%3.7M31.7M495.24K
2026-06-156.29%2.0M31.7M456.89K
2026-05-295.65%1.8M31.7M481.36K
2026-05-155.40%1.7M31.7M487.05K
2026-04-305.72%1.9M32.9M534.49K
2026-04-155.61%1.7M31.1M620.48K
2026-03-315.06%1.6M30.8M753.40K
2026-03-134.66%1.4M29.0M683.30K
2026-02-274.40%1.3M29.0M685.46K
2026-02-134.62%1.3M29.0M644.58K
2026-01-303.43%0.9M26.5M587.59K
2026-01-154.78%1.1M22.7M596.43K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.501.055.900.0036.1710.000.000.968-0.0130.001
call5.000.001.451.202.8441,26310.000.726-0.0450.003
call7.500.004.900.055.4022160.000.552-0.1110.004
call10.000.001.600.066.69810.000.000.504-0.1380.004
call12.500.001.900.007.5770.000.000.480-0.1560.004
call15.000.004.900.008.2390.000.000.464-0.1690.004
put2.500.000.050.003.2710.000.00-0.033-0.0120.001
put5.000.050.450.352.5981,7370.00-0.274-0.0440.003
put7.500.002.652.004.2401.000.00-0.448-0.1100.004
put10.001.706.503.809.3111.000.00-0.496-0.1370.004
put12.504.209.000.0010.1770.000.00-0.520-0.1550.004
put15.006.7011.500.0010.8350.000.00-0.536-0.1680.004

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-028-KCurrent report2026-10-02SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-06-30144Filing for proposed sale of securities under Rule 144.SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-128-KCurrent report2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-088-KCurrent report2026-05-08SEC
2026-05-0810-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-27SCHEDULE 13GSEC
2026-04-244Statement of changes in beneficial ownership of securities2026-04-23SEC
2026-04-21ARSAnnual report to security holders. 2025-12-31SEC
2026-04-21DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-21DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-10SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-01SEC
2026-04-01144Filing for proposed sale of securities under Rule 144.SEC
2026-03-24S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-03-24S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-03-2410-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-248-KCurrent report2026-03-24SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-06001.58M2
2026-050000
2026-0400157.08K1
2026-0300150.89K1
2026-0200139.37K1
2026-01004.85M3
2025-1200917.91K2
2025-110000

Institutional holders

Manager% owned
a16z Capital Management, L.L.C.7.27%
BlackRock, Inc.6.41%
Sofinnova Investments, Inc.5.16%
Jupiter Topco LLC4.82%
Octagon Capital Advisors LP3.93%
RA CAPITAL MANAGEMENT, L.P.3.76%
MPM BioImpact LLC3.75%
VANGUARD CAPITAL MANAGEMENT LLC3.47%
Polar Capital Holdings Plc2.41%
BRAIDWELL LP2.32%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.57%
iShares Russell 2000 ETF2.06%
Fidelity Small Cap Index Fund0.87%
VANGUARD EXTENDED MARKET INDEX FUND0.83%
iShares Russell 2000 Value ETF0.67%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF0.59%
iShares Biotechnology ETF0.50%
Nuveen Quant Small Cap Equity Fund0.45%
VANGUARD RUSSELL 2000 INDEX FUND0.44%
Fidelity Enhanced Small Cap Core ETF0.39%

OakChart. BIOA. Cached 15 minutes.